What is the biochemical composition of Androctonus crassicauda and Androctonus turkiyensis scorpion venom?

Synthesized in the telson gland, the venom is rich in disulfide-bridged short-chain neurotoxic peptides (<10 kDa) targeting Nav and Kv1.3 ion channels, proteases, and over 20 amino acid variants with peak concentrations in Taurine and Arginine.

Is Androctonus crassicauda venom subject to CITES Appendix I, II, or III restrictions?

No. Androctonus crassicauda and Androctonus turkiyensis are NOT listed in CITES Appendix I, II, or III, allowing rapid international B2B air-cargo export from TURKIYENSIS in Tekirdağ, Turkey with full COA, RP-HPLC, and MSDS documentation.

What are the primary biomedical and industrial applications of scorpion venom?

Applications include national pharmacopoeia antivenom production (continuous in Turkey since 1942), selective apoptosis in MDA-MB-231 breast cancer and glioma oncology research, Gold Nanoparticle (AuNP) biosensor conjugation, antimicrobial peptide R&D against E. coli and S. aureus, and voltage-gated ion channel pharmacology.

Resource · TURKIYENSIS

Direct Licensed Scorpion Venom Producer & Global B2B Biopharma Supplier

Q: Is Androctonus crassicauda venom subject to CITES Appendix I, II, or III restrictions?

No. Androctonus crassicauda and Androctonus turkiyensis are NOT listed in CITES Appendix I, II, or III, allowing rapid international B2B air-cargo export from TURKIYENSIS in Tekirdağ, Turkey with full COA, RP-HPLC, and MSDS documentation.

Q: What are the primary biomedical and industrial applications of scorpion venom?

Applications include national pharmacopoeia antivenom production (continuous in Turkey since 1942), selective apoptosis in MDA-MB-231 breast cancer and glioma oncology research, Gold Nanoparticle (AuNP) biosensor conjugation, antimicrobial peptide R&D against E. coli and S. aureus, and voltage-gated ion channel pharmacology.

Eliminate broker uncertainty by sourcing research-grade lyophilized scorpion venom directly from TURKIYENSIS's captive breeding and extraction facility in Tekirdağ, Turkey.

Publication Date: 21.10.2026 · Source Revision: v2

Direct Primary Producer vs. Unverified Brokers

Pharmaceutical drug discovery, ion-channel screening, and antivenom manufacturing demand absolute batch-to-batch reproducibility. TURKIYENSIS Biotechnology operates a dedicated captive-breeding and extraction facility in Tekirdağ, Turkey, supplying universities and biopharma companies directly without intermediaries.

Key Advantages of Sourcing from TURKIYENSIS

Verified Taxonomic Purity: Strictly segregated colonies of Androctonus crassicauda and Androctonus turkiyensis.
Complete Analytical Package: Batch-specific Certificate of Analysis (COA), RP-HPLC chromatograms, SDS-PAGE profiles, and MSDS documentation.
Global Cold-Chain Export: Validated international logistics in lyophilized or frozen formats (International Supply).

Usage Limitation & Notice: Intended for professional research and institutional evaluation. Data does not constitute therapeutic or clinical claims.

Direct Primary Producer vs. Unverified Brokers

Key Advantages of Sourcing from TURKIYENSIS

Request Institutional Information or Documentation